Name · Coriolis Pharma Research GmbH Address/P.O. Box Postal Code/City Country Contact Person Telephone Fax Email Website Social Media Number of Employees Founded (year) Type of Laboratory Areas of Activity
· · · · · · · · · · · · ·
Fraunhoferstr. 18 b 82152 Martinsried Germany Dr Jörg Müller +49-89-41-77-60-111 +49-89-41-77-60-222 joerg.mueller@coriolis-pharma.com www.coriolis-pharma.com
I 110+ 2008 Contract research and development Formulation excellence for biopharmaceuticals l Liquid and lyophilised formulation development l Lyophilisation process development l Leading analytical competence for biologics l Biophysical characterisation l Higher order structure (HOS) Level: R&D, GMP, S1 (BSL1), S2 (BSL2)
External · Experience with 500+ different Collaborations molecules gained in 1,000+ projects Request for · We successfully serve customers Further Collaborations worldwide in all stages of product development (from early R&D up to marketed products). Our customer range includes small virtual biotech firms, mid-size pharma-biotech up to TOP20 pharma-biotech companies. We’re eager to discuss formulation, stability, and analytical challenges you might face. We provide our customers with expert support on a high-quality scientific level, vast experience in the biopharmaceutical field, flexibility and responsiveness.
Coriolis is a world-leading independent contract research and development organisation specialised in biopharmaceutical formulation and drug product development, including lyophilisation processes and analytical development for proteins, peptides, monoclonal antibodies, RNA/DNA, etc., as well as vaccines. This contains highly concentrated protein formulations or developments for subcutaneous administrations or other complex formulations. This is complemented by outstanding analytical capabilities and know-how in the fields of protein characterisation (e.g. higher order structure characterisation, aggregation, subvisible particles, surfactant characterisation, etc.). Coriolis is expert in highly specialised and innovative analytical technologies (e.g. analytical ultracentrifugation (AUC), Resonant Mass Measurement (RMM), quantitative Far- and Near-UV circular dichroism spectroscopy (CD)). In addition, we also offer as standalone services GMPcompliant analytics for subvisible particle analysis and aggregation characterisation (e.g. light obscuration (LO), flow imaging spectroscopy (MFI), asymmetrical flow field-flow fractionation (AF4)), and other innovative techniques. Most recently we also offer polysorbate analytics such as quantification and characterisation of degradation products. As of 2017 Coriolis has received the regulatory approval for the operation of a genetic engineering facility of safety level S2 (BSL2), allowing handling of S1 and S2 classified samples. For gene therapy and viral based vaccine products Coriolis is equipped with state-of-the-art analytical equipment to support particle morphology, aggregation, size distribution, and purity analysis using e.g. AUC, transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA) and dynamic light scattering (DLS).